Bio-rad Laboratories, Inc. · NYSE:BIO

Bio-rad Laboratories — Barclays Global Healthcare Conference 2018

23 slides from Bio-rad Laboratories's conference presentation, 2018

  1. Slide 1: Bio-Rad Laboratories, Inc. Barclays Global Healthcare Conference 2018

    Bio-Rad Laboratories, Inc. Barclays Global Healthcare Conference 2018

  2. Slide 2: Welcome

    Welcome Norman Schwartz Chief Executive Officer

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding estimated future financial performance or results, the growth of our busin

  4. Slide 4: Company History

    Company History 1966: Sales approach $1 million. Company 1969: 1986: goes public raising Introduce $140,000. First Bio-Rad introduces 1978: 1982: 1952: David & Alice Schwartz gel electrophoresis. First commercial test First test for first confirmation establish Bio-Rad to accelerate international of

  5. Slide 5: Company History

    Company History 2014: Begin reorganization with major investments in infrastructure improvements. 1998: 2011: 1991: Enter DNA Sales reach $2 billion. Introduction of the amplification 2000: 2005: 7,000 employees 2013 – 2017: first Hemoglobin market with worldwide. Acquire Major deployments of Sales

  6. Slide 6: Bio-Rad Today

    Bio-Rad Today Continuous 60+ Years Strong Innovation A History of Contribution Performance $2B+ Annual Sales Key Competencies Fueling Ongoing Growth Complementary 8,000+ Employees Worldwide Business Mix Leveraging Across the Company Providing Solutions to Advance Scientific Discovery and Improve Hea

  7. Slide 7: Bio-Rad Global Profile

    Bio-Rad Global Profile Applied 3% BioPharma Asia 9% EMEA 19% Hospital Labs 38% 35% Academic 23% Customers Geography Products Transfusion Labs Reference Labs Americas 15% 15% 43% Diversified Customer Base Worldwide Presence Broad Product Base

  8. Slide 8: Leading Market Positions

    Leading Market Positions Diagnostics Life Science  Autoimmune testing   Diabetes Monitoring Bio-chromatography Digital  DNA Amplification  HIV testing Biology  Blood Typing  Electrophoresis  Gel Image Analysis  Quality Controls  Protein Assays 80%+ of Sales from Products in which Bio-Rad h

  9. Slide 9: Life Science Profile

    Life Science Profile Highlights  Market Size: $45B–50B  Market Growth 4% CAGR  Addressable Market: $8–9B Asia 26% Americas Research Applied Markets 43% Revenue Consumables 63% 7% Geography 48% Customer Products Segments EMEA BioPharma 31% Instruments/ Apparatus 30% 52% Source: Bio-Rad Internal 9

  10. Slide 10: Life Science

    Life Science Research BioPharma Applied Markets  Academic & Industrial Research  Discovery  Food Safety  Amplification &  Pre-Clinical Research and Quality Testing Gene Expression  Clinical Research  Water Quality Testing  Bio-chromatography  Manufacturing and  Wine Quality Testing  Prote

  11. Slide 11: Life Science: Investing for the future

    Investing for the future  Continue to drive core technologies growth  Expand in new and growing markets with streamlined workflows and solutions  Focus on the needs of translational Life Science researchers and BioPharma  Invest in informatics solutions to turn data into knowledge  Continue dev

  12. Slide 12: Clinical Diagnostics Profile

    Clinical Diagnostics Profile Highlights  Market Size: $55-60B Asia  Addressable Market: $5.5B 19%  Market Growth ~ 5% EMEA 39% Instruments Transfusion Revenue 25% Laboratory Geography 18% Customer Products Segments Hospital Americas Laboratory 42% Reference 61% Laboratory Reagents 21% 75% Source:

  13. Slide 13: Clinical Diagnostics

    Clinical Diagnostics Diagnostic Testing Protecting the Quality and Monitoring Blood Supply Assurance  Diabetes  Blood Typing  Quality Controls  Infectious Disease  Blood Virus Screening  Quality Assessments  Autoimmune  HIV Confirmation Testing  Data Management  Transfusion Compatibility W

  14. Slide 14: Clinical Diagnostics: Investing for the future

    Investing for the future  Blood Typing in North America  Microbiome MDx Panels Clinical  New Quality Control Segments Diagnostics  Track Capability  IH-500 and D-100 Systems in China  Point of Care MDx 14

  15. Slide 15: Digital PCR Profile

    Digital PCR Profile Highlights  North America and China are regional growth drivers  BioPharma fueling growth in diagnostic applications  Foundational intellectual property (IP) position Asia Liquid Biopsy/ 29% Consumables Diagnostic BioPharma 20% EMEA 32% 30% 26% Revenue Geography Customer Segme

  16. Slide 16: Digital Biology Product Markets

    Digital Biology Product Markets Life Science Droplet Digital PCR Diagnostics applications span Hospital + Commercial Basic + Applied Research Laboratories research, applied & Laboratories diagnostic markets  Droplet Digital PCR  Droplet Digital PCR Single-Cell NGS  Single-Cell RNA-Seq sample prep

  17. Slide 17: Digital Biology: Investing for the future

    Investing for the future Simplify the Digital PCR Workflow with Next Generation Platforms Bio-Pharma and diagnostics applications Increase Capability Digital Higher multiplexing for ddPCR Expand ddPCR Assay Menu Biology Applied and IVD oncology markets Provide Droplet-Based NGS Sample Prep Solutions

  18. Slide 18: Transformational Changes

    Transformational Changes ERP ROLLOUT Europe Live (April 2017) STRUCTURAL CHANGE Divisional  Functional GLOBAL ORGANIZATIONS Supply Chain + Commercial SHARED SERVICE HUBS Accounting + Corporate

  19. Slide 19: The Path Forward

    The Path Forward  Geographic Expansion  Optimized Supply Chain  New Products  Reduced ERP Spend  New Markets Driving Expanding  Shared Services Revenue EBITDA  Operating Leverage Growth Margins  Increased Cash Flow Creating Accelerating  Higher Profitability Shareholder Free Cash  Discipli

  20. Slide 20: Long Term Goals

    Long Term Goals Targets: 3-5% Revenue Growth 20+ % Profitability Creating (Currency Neutral) (Adjusted EBITDA Margin) Shareholder Value 20

  21. Slide 21: 2018 Outlook

    2018 Outlook  Opportunity for Sales Growth  Stable Geographic markets  Research funding holding steady  Good momentum for new products  Expansion into U.S. Blood Typing market  Return on Internal Investments  New product areas such as droplet digital PCR and cell biology  Global ERP and IT r

  22. Slide 22: Summary – Closing remarks

    Summary – Closing remarks  Investments at an inflection point  Building on our market and product leadership  Increased focus on acquisition opportunities  Leveraging our new organization, operating model and systems to drive value

  23. Slide 23: Bio-Rad Laboratories, Inc. Barclays Global Healthcare Conference

    Bio-Rad Laboratories, Inc. Barclays Global Healthcare Conference 2018

Bio-Rad Laboratories — Barclays Global Healthcare Conference 2018 on 6ix